Masimo (NASDAQ:MASI) issued an update on its FY19 earnings guidance on Wednesday morning. The company provided EPS guidance of $3.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.04. The company issued revenue guidance of $910 million, compared to the consensus revenue estimate of $906.53 million.
NASDAQ:MASI opened at $113.16 on Friday. Masimo has a 52 week low of $80.69 and a 52 week high of $126.89. The company has a market capitalization of $5.94 billion, a P/E ratio of 46.19, a PEG ratio of 2.36 and a beta of 0.99.
Masimo (NASDAQ:MASI) last announced its earnings results on Wednesday, October 31st. The medical equipment provider reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.02. The firm had revenue of $210.58 million during the quarter, compared to analysts’ expectations of $207.62 million. Masimo had a return on equity of 20.29% and a net margin of 17.08%. The company’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.56 earnings per share. Analysts expect that Masimo will post 2.92 EPS for the current fiscal year.
MASI has been the subject of a number of recent analyst reports. BidaskClub cut Masimo from a buy rating to a hold rating in a research report on Tuesday, November 13th. Stifel Nicolaus upped their target price on Masimo from $112.00 to $145.00 and gave the stock a buy rating in a research report on Tuesday, October 2nd. Zacks Investment Research cut Masimo from a hold rating to a sell rating in a research report on Thursday, January 3rd. Piper Jaffray Companies increased their price objective on Masimo to $120.00 and gave the company a neutral rating in a research report on Thursday, November 1st. Finally, UBS Group started coverage on Masimo in a research report on Tuesday, November 27th. They issued a buy rating and a $137.00 price objective for the company. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $119.00.
In other news, COO Anand Sampath sold 30,000 shares of the stock in a transaction that occurred on Wednesday, November 28th. The stock was sold at an average price of $110.00, for a total value of $3,300,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Sanford Fitch sold 2,000 shares of the stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $110.90, for a total value of $221,800.00. The disclosure for this sale can be found here. Insiders sold 34,000 shares of company stock valued at $3,748,080 over the last three months. 12.60% of the stock is owned by company insiders.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.